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Abstract. Plerixafor (also known as Mozobil®, AMD3100) is an immunostimulating agent 
approved by FDA in 2008 and widely used in the therapy of hematological malignancies1. This compound 
is a polyamine consisting of two cyclam rings connected by a p-xylylene linker. The existing synthetic 
strategies towards plerixafor are discussed in a recent review.2 To date, a variety of plerixafor structural 
analogs containing a p-xylylenediamine fragment are known. Some of them exhibit biological activity 
similar to that of the original drug.3 
We have synthesized new structural analogs of plerixafor, in which both cyclam fragments are 
replaced by other nitrogen-containing moieties, such as cyclic or acyclic amines and amides. The synthetic 
procedure included a double donor–acceptor cyclopropane ring-opening with nitrogen-containing 
nucleophiles (azide, thiocyanate, etc.) in protic ionic liquid media acting as both a solvent and an acidic 




1. De Clercq E. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration / E. 
De Clercq // Antiviral Chem. Chemother. – 2019. – Vol. 27. – P. 1–8. 
2. Ratmanova N. K. Methods for the synthesis of immunostimulant plerixafor / N. K. Ratmanova, I. A. Andreev, I. V. 
Trushkov // Chem. Heterocycl. Comp. – 2020. – Vol. 56. – P. 30–35. 
3. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential 
/ D. Peng, B. Cao, Y.-J. Zhou [et al.] // Eur. J. Med. Chem. – 2018. – Vol. 149. – P. 148–169. 
 
This work was supported by the Russian Foundation for Basic Research (project # 20-33-70014) and the President of the 
Russian Federation scholarship for young scientists, working on R&D in top-priority areas vital to the modernization of the 
Russian economy (medical technologies area, # СП-278.2019.4). 
  
